These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 32820369)

  • 1. Promising clinical performance of pretargeted immuno-PET with anti-CEA bispecific antibody and gallium-68-labelled IMP-288 peptide for imaging colorectal cancer metastases: a pilot study.
    Touchefeu Y; Bailly C; Frampas E; Eugène T; Rousseau C; Bourgeois M; Bossard C; Faivre-Chauvet A; Rauscher A; Masson D; David A; Cerato E; Carlier T; Sharkey RM; Goldenberg DM; Barbet J; Kraeber-Bodere F; Bodet-Milin C
    Eur J Nucl Med Mol Imaging; 2021 Mar; 48(3):874-882. PubMed ID: 32820369
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immuno-PET Using Anticarcinoembryonic Antigen Bispecific Antibody and 68Ga-Labeled Peptide in Metastatic Medullary Thyroid Carcinoma: Clinical Optimization of the Pretargeting Parameters in a First-in-Human Trial.
    Bodet-Milin C; Faivre-Chauvet A; Carlier T; Rauscher A; Bourgeois M; Cerato E; Rohmer V; Couturier O; Drui D; Goldenberg DM; Sharkey RM; Barbet J; Kraeber-Bodere F
    J Nucl Med; 2016 Oct; 57(10):1505-1511. PubMed ID: 27230928
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pretargeted immuno-positron emission tomography imaging of carcinoembryonic antigen-expressing tumors with a bispecific antibody and a 68Ga- and 18F-labeled hapten peptide in mice with human tumor xenografts.
    Schoffelen R; Sharkey RM; Goldenberg DM; Franssen G; McBride WJ; Rossi EA; Chang CH; Laverman P; Disselhorst JA; Eek A; van der Graaf WT; Oyen WJ; Boerman OC
    Mol Cancer Ther; 2010 Apr; 9(4):1019-27. PubMed ID: 20354120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-CEA Pretargeted Immuno-PET Shows Higher Sensitivity Than DOPA PET/CT in Detecting Relapsing Metastatic Medullary Thyroid Carcinoma: Post Hoc Analysis of the iPET-MTC Study.
    Bodet-Milin C; Faivre-Chauvet A; Carlier T; Ansquer C; Rauscher A; Frampas E; Toulgoat F; Masson D; Bourgeois M; Cerato E; Rohmer V; Couturier O; Drui D; Goldenberg DM; Sharkey RM; Barbet J; Kraeber-Bodere F
    J Nucl Med; 2021 Sep; 62(9):1221-1227. PubMed ID: 33547213
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immuno-PET of colorectal cancer with a CEA-targeted [68 Ga]Ga-nanobody: from bench to bedside.
    Li L; Lin X; Wang L; Ma X; Zeng Z; Liu F; Jia B; Zhu H; Wu A; Yang Z
    Eur J Nucl Med Mol Imaging; 2023 Oct; 50(12):3735-3749. PubMed ID: 37382662
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Initial Clinical Results of a Novel Immuno-PET Theranostic Probe in Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer.
    Rousseau C; Goldenberg DM; Colombié M; Sébille JC; Meingan P; Ferrer L; Baumgartner P; Cerato E; Masson D; Campone M; Rauscher A; Fleury V; Labbe C; Chauvet AF; Fresnel JS; Toquet C; Barbet J; Sharkey RM; Campion L; Kraeber-Bodéré F
    J Nucl Med; 2020 Aug; 61(8):1205-1211. PubMed ID: 32169921
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of an imaging-guided CEA-pretargeted radionuclide treatment of advanced colorectal cancer: first clinical results.
    Schoffelen R; Boerman OC; Goldenberg DM; Sharkey RM; van Herpen CM; Franssen GM; McBride WJ; Chang CH; Rossi EA; van der Graaf WT; Oyen WJ
    Br J Cancer; 2013 Aug; 109(4):934-42. PubMed ID: 23860529
    [TBL] [Abstract][Full Text] [Related]  

  • 8. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pretargeted immuno-PET and radioimmunotherapy of prostate cancer with an anti-TROP-2 x anti-HSG bispecific antibody.
    van Rij CM; Lütje S; Frielink C; Sharkey RM; Goldenberg DM; Franssen GM; McBride WJ; Rossi EA; Oyen WJ; Boerman OC
    Eur J Nucl Med Mol Imaging; 2013 Sep; 40(9):1377-83. PubMed ID: 23674207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive patient-specific dosimetry and individualized dosing of pretargeted radioimmunotherapy in patients with advanced colorectal cancer.
    Schoffelen R; Woliner-van der Weg W; Visser EP; Goldenberg DM; Sharkey RM; McBride WJ; Chang CH; Rossi EA; van der Graaf WT; Oyen WJ; Boerman OC
    Eur J Nucl Med Mol Imaging; 2014 Aug; 41(8):1593-602. PubMed ID: 24643780
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metastatic human colonic carcinoma: molecular imaging with pretargeted SPECT and PET in a mouse model.
    Sharkey RM; Karacay H; Vallabhajosula S; McBride WJ; Rossi EA; Chang CH; Goldsmith SJ; Goldenberg DM
    Radiology; 2008 Feb; 246(2):497-507. PubMed ID: 18227543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel Carcinoembryonic-Antigen-(CEA)-Specific Pretargeting System to Assess Tumor Cell Viability after Irradiation of Colorectal Cancer Cells.
    Meller B; Rave-Fränck M; Breunig C; Schirmer M; Baehre M; Nadrowitz R; Liersch T; Meller J
    Strahlenther Onkol; 2011 Feb; 187(2):120-6. PubMed ID: 21271227
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum carcinoembryonic antigen measurement, abdominal contrast-enhanced computed tomography, and fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography in the detection of colorectal cancer recurrence: a correlative study.
    Ozkan E; Soydal C; Araz M; Aras G
    Nucl Med Commun; 2012 Sep; 33(9):990-4. PubMed ID: 22842225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The utility of FDG-PET/CT as an effective tool for detecting recurrent colorectal cancer regardless of serum CEA levels.
    Sanli Y; Kuyumcu S; Ozkan ZG; Kilic L; Balik E; Turkmen C; Has D; Isik G; Asoglu O; Kapran Y; Adalet I
    Ann Nucl Med; 2012 Aug; 26(7):551-8. PubMed ID: 22644560
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Souteiro P; Gouveia P; Ferreira G; Belo S; Costa C; Carvalho D; Duarte H; Sampaio IL
    Endocrine; 2019 May; 64(2):322-329. PubMed ID: 30684230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective study on diagnostic and prognostic significance of postoperative FDG PET/CT in recurrent colorectal carcinoma patients: comparison with MRI and tumor markers.
    Odalovic S; Stojiljkovic M; Sobic-Saranovic D; Pandurevic S; Brajkovic L; Milosevic I; Grozdic-Milojevic I; Artiko V
    Neoplasma; 2017; 64(6):954-961. PubMed ID: 28895416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sensitivity of pretargeted immunoPET using
    Foubert F; Gouard S; Saï-Maurel C; Chérel M; Faivre-Chauvet A; Goldenberg DM; Barbet J; Bailly C; Bodet-Milin C; Carlier T; Kraeber-Bodéré F; Touchefeu Y; Frampas E
    Oncotarget; 2018 Jun; 9(44):27502-27513. PubMed ID: 29938001
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of 18F-FDG PET/CT in detecting colorectal cancer recurrence in patients with elevated CEA levels.
    Ozkan E; Soydal C; Araz M; Kir KM; Ibis E
    Nucl Med Commun; 2012 Apr; 33(4):395-402. PubMed ID: 22367859
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pretargeted immunoPET of prostate cancer with an anti-TROP-2 x anti-HSG bispecific antibody in mice with PC3 xenografts.
    van Rij CM; Frielink C; Goldenberg DM; Sharkey RM; Franssen GM; Lütje S; McBride WJ; Oyen WJ; Boerman OC
    Mol Imaging Biol; 2015 Feb; 17(1):94-101. PubMed ID: 25060065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survival Outcomes in Asymptomatic Patients With Normal Conventional Imaging but Raised Carcinoembryonic Antigen Levels in Colorectal Cancer Following Positron Emission Tomography-Computed Tomography Imaging.
    Khan K; Athauda A; Aitken K; Cunningham D; Watkins D; Starling N; Cook GJ; Kalaitzaki E; Chau I; Rao S
    Oncologist; 2016 Dec; 21(12):1502-1508. PubMed ID: 27742904
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.